Paris: Sanofi shares rose by more than 2 per cent in early Paris stock market trading on Monday as the company updated investors on some of its ongoing trials for potential multiple sclerosis (MS) treatments.
The drugmaker said two Phase III trials showed that its experimental daily pill tolebrutinib was not better than its established MS drug Aubagio in reducing relapse rates in a highly common form of MS, while a separate late-stage trial showed the pill met the main goal to treat another form of MS.
Sanofi shares were up 2.5 per cent by 0710 GMT, making the stock the best performer on Paris’ benchmark CAC-40 equity index.
(Reporting by Tassilo Hummel; Editing by Sudip Kar-Gupta)
